login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
ENLIVEN THERAPEUTICS INC (ELVN) Stock News
USA
- NASDAQ:ELVN -
US29337E1029
-
Common Stock
21.19
USD
-0.93 (-4.2%)
Last: 10/21/2025, 8:10:41 PM
21.19
USD
0 (0%)
After Hours:
10/21/2025, 8:10:41 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ELVN Latest News, Press Relases and Analysis
All
Press Releases
a month ago - By: Zacks Investment Research
Enliven Therapeutics, Inc. (ELVN) Upgraded to Buy: Here's What You Should Know
2 months ago - By: Zacks Investment Research
How Much Upside is Left in Enliven Therapeutics, Inc. (ELVN)? Wall Street Analysts Think 102.41%
2 months ago - By: Enliven Therapeutics, Inc.
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting
2 months ago - By: The Motley Fool
Enliven Posts Loss Beat and Cash Surge
a year ago - By: InvestorPlace
ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q2 2024
2 months ago - By: Enliven Therapeutics, Inc.
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
4 months ago - By: Benzinga
- Mentions:
ROST
CMG
CNC
MO
...
Meta To Rally Around 3%? Here Are 10 Top Analyst Forecasts For Wednesday
4 months ago - By: Stocktwits
- Mentions:
GS
Enliven Short Interest Falls To 14-Month Low After Leukemia Trial Data, Goldman Initiates With ‘Buy’
4 months ago - By: Yahoo Finance
- Mentions:
GS
NVS
NOVN
Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data
4 months ago - By: Enliven Therapeutics, Inc.
Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
a year ago - By: BusinessInsider
ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q2 2024
4 months ago - By: Yahoo Finance
- Mentions:
KULR
CRWV
NOVN
Why KULR Technology Stock Is Plummeting Today
4 months ago - By: Benzinga
- Mentions:
TLSA
HCTI
SNES
NCNA
...
12 Health Care Stocks Moving In Friday's Intraday Session
4 months ago - By: Enliven Therapeutics, Inc.
Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
4 months ago - By: Enliven Therapeutics, Inc.
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
4 months ago - By: Enliven Therapeutics, Inc.
Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress
a year ago - By: BusinessInsider
ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q1 2024
5 months ago - By: Enliven Therapeutics, Inc.
Enliven Therapeutics to Present at Upcoming Investor Conferences
5 months ago - By: Yahoo Finance
Enliven price target lowered to $27 from $36 at JonesResearch
5 months ago - By: Enliven Therapeutics, Inc.
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
5 months ago - By: Enliven Therapeutics, Inc.
Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress
7 months ago - By: Enliven Therapeutics, Inc.
Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting
7 months ago - By: Enliven Therapeutics, Inc.
Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
8 months ago - By: Enliven Therapeutics, Inc.
Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
a year ago - By: Enliven Therapeutics, Inc.
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
a year ago - By: Enliven Therapeutics, Inc.
Enliven Therapeutics to Present at the Jefferies London Healthcare Conference
a year ago - By: Enliven Therapeutics, Inc.
Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
a year ago - By: Enliven Therapeutics, Inc.
Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML
a year ago - By: Enliven Therapeutics, Inc.
Enliven Therapeutics to Present at Two Upcoming Investor Conferences
Please enable JavaScript to continue using this application.